Summarized by Masters of Longevity from GlobeNewswire - Biotech Financing.
Rewind secured additional financing to advance an oral GPR17 antagonist toward clinical testing for multiple sclerosis. The amount raised was not disclosed.
Key Takeaways
- The financing will support studies required before the program can enter clinical testing.
- Animal studies showed improved myelin repair and functional recovery after treatment.
- The reported findings do not establish safety or clinical benefit in patients.
